Efficacy and safety of Saccharomyces boulardii for acute diarrhea

Pediatrics

Volumn 134, Issue 1, 2014, Pages

  Feizizadeh, Sahar ^a   Salehi Abargouei, Amin ^b   Akbari, Vajihe ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute diarrhea; Children; Efficacy and systematic review; Saccharomyces boulardi; Safety

Indexed keywords

PROBIOTIC AGENT;

ACUTE DIARRHEA; CAUSAL ATTRIBUTION; CHILD HOSPITALIZATION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SACCHAROMYCES BOULARDII; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ACUTE DIARRHEA; CHILDREN; EFFICACY AND SYSTEMATIC REVIEW; SACCHAROMYCES BOULARDI; SAFETY;

ACUTE DISEASE; BIOLOGICAL THERAPY; CHILD; DIARRHEA; HUMANS; REMISSION INDUCTION; SACCHAROMYCES;

EID: 84904161657     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-3950     Document Type: Review

References (61)

1. Pawlowski SW, Warren CA, Guerrant R. Diagnosis and treatment of acute or persistent diarrhea. Gastroenterology. 2009;136(6):1874-1886
2. Nataro JP. Diarrhea among children in developing countries. Adv Exp Med Biol. 2013;764:73-80
3. World Health Organization. Medi center. Diarrhoeal disease. April 2013. Available at: www.who.int/mediacentre/factsheets/fs330/en/. Accessed September 14, 2013
4. Guarino A, Lo Vecchio A, Canani RB. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol. 2009;25(1):18-23
5. Matsuzaki T, Chin J. Modulating immune responses with probiotic bacteria. Immunol Cell Biol. 2000;78(1):67-73 (Pubitemid 30090991)
6. Cheikhyoussef A, Pogori N, Chen W, Zhang H. Antimicrobial proteinaceous compounds obtained from bifidobacteria: from production to their application. Int J Food Microbiol. 2008;125(3):215-222
7. Abedi D, Feizizadeh S, Akbari V, Jafarian-Dehkordi A. In vitro anti-bacterial and anti-adherence effects of Lactobacillus delbrueckii subsp bulgaricus on Escherichia coli. Res Pharm Sci. 2013;8(4):260-268
8. Mombelli B, Gismondo MR. The use of probiotics in medical practice. Int J Antimicrob Agents. 2000;16(4):531-536
9. Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107(6):922-931
10. Szajewska H, Skórka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25(3):257-264 (Pubitemid 46115395)
11. Szajewska H, Skórka A. Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment Pharmacol Ther. 2009;30(9):960-961
12. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269, W64
13. Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 2006;12(28):4557-4560 (Pubitemid 44256346)
14. Canani RB, Cirillo P, Terrin G, et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. Br Med J. 2007;335(7615):340-342 (Pubitemid 47310868)
15. Chouraqui JP, Dietsch J, Musial C, Blehaut H. Saccharomyces boulardii (SB) in the management of toddler diarrhea: a double-blind placebo-controlled study. [Abstract] J Pediatr Gastroenterol Nutr. 1995;463. Available at: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/500/CN-00335500/ frame.html. Accessed September 12, 2013
16. Dalgic N, Sancar M, Bayraktar B, Pullu M, Hasim O. Probiotic, zinc and lactose-free formula in children with rotavirus diarrhea: are they effective? Pediatr Int. 2011;53(5):677-682
17. Htwe K, Yee KS, Tin M, Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg. 2008;78(2):214-216 (Pubitemid 351844552)
18. Hüseynova NM, Qurbanov MK, Ezizov NA, Kerimova TA. The effect of Yomogi preparation in treatment of severe diarrea in children. Uşaqlarda kinverted e signskin diareyalarin müalicinverted e signsindinverted e sign Yomogi preparatinin effekti vliyi. 2011(2):41-43
19. Khan A, Javed T, Chishti AL. Clinical efficacy of use of probiotic "Saccharomyces boulardii" in children with acute watery diarrhea. Pakistan Paed J. 2012;36(3):122-127
20. Kumar S, Siyal AA, Brohi AR. Evaluation of the efficacy of Saccharomyces boulardii in children with acute diarrhea. Medical Forum Monthly. 2011;22(6):36-39
21. Higgins JPT, Green S,eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration; 2011 [updated March 2011]
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188 (Pubitemid 17189972)
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558 (Pubitemid 34746062)
24. Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care: Meta-Analysis in Context, 2nd ed. London: BMJ; 2001
25. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr. 2004;50(4):234-236 (Pubitemid 39136891)
26. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583-590 (Pubitemid 40381510)
27. Czerwionka-Szaflarska M, Adamska I, Szaflarska-Popławska A, Romańczuk B. Saccharomyces boulardii in the prevention of antibioticassociated diarrhoea - Our experience. Saccharomyces boulardii w profilaktyce biegunki zwizanej z antybiotykoterapia - doświadczenia własne. Pediatr Pol. 2012;87(1):14-18
28. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr. 1993;16(4):419-425 (Pubitemid 23143772)
29. Eren M, Dinleyici EC, Vandenplas Y. Clinical efficacy comparison of Saccharomyces boulardii and yogurt fluid in acute nonbloody diarrhea in children: a randomized, controlled, open label study. Am J Trop Med Hyg. 2010;82(3):488-491
30. Le Luyer B, Makhoul G, Duhamel JF. [A multicentric study of a lactose free formula supplemented with Saccharomyces boulardii in children with acute diarrhea]. Arch Pediatr. 2010;17(5):459-465
31. Castañeda GC, García BE, Santa Cruz DM, Fernandez GM, Monterrey GP. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Revista Mexicana de Puericultura y Pediatría. 1995;2(12):1-11. Available at: http://onlinelibrary.wiley. com/o/cochrane/clcentral/articles/305/CN-00836305/frame.html. Accessed October 4, 2013
32. Gaón D, García H, Winter L, et al. Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires). 2003;63(4):293-298 (Pubitemid 37138872)
33. Cetina Sauri G, Sierra Basto G. [Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea]. Trib méd (Bogotá). 1990;81:141-144. Available at: http://onlinelibrary.wiley.com/o/cochrane/ clcentral/articles/415/CN-00479415/frame.html. Accessed September 12, 2013
34. Cetina-Sauri G, Sierra Basto G. Therapeutical evaluation of S. boulardii in children with acute diarrhea. Compendium De Investigaciones clinicas Latinoamericanas. 1989;9(3):108-112
35. Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res. 2011;108(3):541-545
36. Teran CG, Teran-Escalera CN, Villarroel P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int J Infect Dis. 2009;13(4):518-523
37. Burande MA. Comparison of efficacy of Saccharomyces boulardii strain in the treatment of acute diarrhea in children: a prospective, single-blind, randomized controlled clinical trial. J Pharmacol Pharmacother. 2013;4(3):205
38. Vandenplas Y, Badriul H, Thapa B, Elizabeth K, Bhave S. A multi-center dbrpc-trial in developing countries with Saccharomyces boulardii (S. boulardii) in acute gastroenteritis. Paper presented at European Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting, 2007
39. Chapoy P. [Treatment of acute infantile diarrhea: controlled trial of Saccharomyces boulardii]. Ann Pediatr (Paris). 1985;32(6):561-563
40. Hernandez CL, Pineda EE, Jimenez MIR, Lucena MS. Clinical therapeutic affect of Saccharomyces boulardii on children with acute diarrhea. Revista de Enfermedades Infecciosas en Pediatria. 1998;11(43):87-89. Available at: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/307/CN-00836307/ frame.html. Accessed October 4, 2013
41. Kurugöl Z, Koturoǧlu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr. 2005;94(1):44-47 (Pubitemid 40127932)
42. Urganci N, Polat T, Uysalol M, Çetinkaya F. Evaluation of the efficacy of Saccharomyces boulardii in children with acute diarrhoea. Arch Gastroenterohepatol. 2001;20(3-4):81-83 (Pubitemid 34269692)
43. Corrêa NB, Penna FJ, Lima FM, Nicoli JR, Filho LA. Treatment of acute diarrhea with Saccharomyces boulardii in infants. J Pediatr Gastroenterol Nutr. 2011;53(5):497-501
44. Grandy G, Medina M, Soria R, Terán CG, Araya M. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infect Dis. 2010;10:253
45. Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr. 2012;79(4):478-482
46. Dinleyici EC, Eren M, Yargic ZA, Dogan N, Vandenplas Y. Clinical efficacy of Saccharomyces boulardii and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study. Am J Trop Med Hyg. 2009;80(6):953-955
47. Hafeez A, Tariq P, Ali S, Kundi ZU, Khan A, Hassan M. The efficacy of Saccharomyces boulardii in the treatment of acute watery diarrhea in children: a multicentre randomized controlled trial. J Coll Physicians Surgeons Pakistan. 2002;12(7):432-434 (Pubitemid 34947157)
48. Villarruel G, Rubio DM, Lopez F, et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr. 2007;96(4):538-541 (Pubitemid 46466118)
49. Erdoǧan Ö, Tanyeri B, Torun E, et al. The comparison of the efficacy of two different probiotics in rotavirus gastroenteritis in children. J Trop Med. 2012; 2012:1-5
50. Ozkan TB, Sahin E, Erdemir G, Budak F. Effect of Saccharomyces boulardii in children with acute gastroenteritis and its relationship to the immune response. J Int Med Res. 2007;35(2):201-212 (Pubitemid 46831068)
51. Cetina-Sauri G, Sierra Basto G. Evaluation of Saccharomyces boulardii for the treatment of acute diarrhea in pediatric patients. Ann Pediatr. 1994;41(6):397-400 (Pubitemid 24228863)
52. Savaş-Erdeve S, Gökay S, Dallar Y. Efficacy and safety of Saccharomyces boulardii in amebiasis-associated diarrhea in children. Turk J Pediatr. 2009;51(3):220-224
53. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr. 2001;33(suppl 2):S17-S25 (Pubitemid 33070120)
54. Zbinden R. Inhibition of Saccharomyces boulardii (nom. inval.) on cell invasion of Salmonella typhimurium and Yersinia enterocolitica. Microb Ecol Health Dis. 1999;11(3):158-162
55. Geyik MF, Aldemir M, Hosoglu S, et al. The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice. Ann R Coll Surg Engl. 2006;88(2):176-180
56. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104(4):1108-1115 (Pubitemid 23090764)
57. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun. 2000;68(10):5998-6004
58. Buts J-P, Bernasconi P, Vaerman J-P, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci. 1990;35(2):251-256 (Pubitemid 20072201)
59. Colbère-Garapin F, Martin-Latil S, Blondel B, et al. Prevention and treatment of enteric viral infections: possible benefits of probiotic bacteria. Microbes Infect. 2007;9(14-15):1623-1631 (Pubitemid 350217090)
60. Rigothier MC, Maccario J, Gayral P. Inhibitory activity of saccharomyces yeasts on the adhesion of Entamoeba histolytica trophozoites to human erythrocytes in vitro. Parasitol Res. 1994;80(1):10-15 (Pubitemid 24076345)
61. Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer. 2000;8(6):504-505